English

Antiretroviral treatment (tblART)

26 forms  
Antiretroviral treatment
Description

Antiretroviral treatment

Alias
UMLS CUI-1
C1963724
UMLS CUI-2
C0019682
Patient ID
Description

PATIENT

Data type

text

Alias
UMLS CUI [1]
C2348585
Represents the antiretroviral treatment
Description

ART_ID

Data type

text

Alias
UMLS CUI [1]
C1963724
Date of initiation of treatment
Description

ART_SD

Data type

date

Alias
UMLS CUI [1,1]
C1963724
UMLS CUI [1,2]
C0808070
Date of stopping treatment
Description

ART_ED

Data type

date

Alias
UMLS CUI [1,1]
C1963724
UMLS CUI [1,2]
C0806020
Reason for stopping treatment
Description

ART_RS

Data type

integer

Alias
UMLS CUI [1,1]
C2133636
UMLS CUI [1,2]
C1963724
Dosage (mg or mL) per intake unless ART_FR=-1
Description

ART_DO

Data type

float

Alias
UMLS CUI [1,1]
C3174092
UMLS CUI [1,2]
C1963724
Frequency
Description

-1 = Frequency not known. ART_DO contains dosage per day 0.33 = 1 dose every third day 0.5 = 1 dose every second day 1 = 1 daily dose/qd 2 = 2 daily doses/bid 3 = 3 daily doses/tid 4... = code gives number of daily doses

Data type

integer

Alias
UMLS CUI [1,1]
C3476109
UMLS CUI [1,2]
C1963724
Start hour and minute of the day
Description

ART_ST

Data type

time

Alias
UMLS CUI [1,1]
C1963724
UMLS CUI [1,2]
C1301880
Stop hour and minute of the day
Description

ART_ET

Data type

time

Alias
UMLS CUI [1,1]
C1963724
UMLS CUI [1,2]
C1522314
Back to the top of the page

Similar models

Antiretroviral treatment (tblART)

26 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Antiretroviral treatment
C1963724 (UMLS CUI-1)
C0019682 (UMLS CUI-2)
PATIENT
Item
Patient ID
text
C2348585 (UMLS CUI [1])
Item
Represents the antiretroviral treatment
text
C1963724 (UMLS CUI [1])
ART_ID
Code List
Represents the antiretroviral treatment
CL Item
ART unspecified (J05A)
CL Item
Beviramat (J05A-BEV)
CL Item
Participant in Blinded Trial (J05A-PBT)
CL Item
PI unspecified (J05AE)
CL Item
Mozenavir (DMP-450) (J05AE-MOZ)
CL Item
Saquinavir (gel, not specified) (J05AE01)
CL Item
Saquinavir hard gel (INVIRASE) (J05AE01-SQH)
CL Item
Saquinavir soft gel (FORTOVASE) (J05AE01-SQS)
CL Item
Indinavir (CRIXIVAN) (J05AE02)
CL Item
Ritonavir (NORVIR) (J05AE03)
CL Item
Ritonavir high dose (NORVIR) (J05AE03-H)
CL Item
Ritonavir low dose (NORVIR) (J05AE03-L)
CL Item
Nelfinavir (VIRACEPT) (J05AE04)
CL Item
Amprenavir (AGENERASE) (J05AE05)
CL Item
Kaletra/Aluvia (Lopinavir/Ritonavir) (J05AR10)
CL Item
Fos-amprenavir (Telzir, Lexiva) (J05AE07)
CL Item
Atazanavir (Reyataz) (J05AE08)
CL Item
Tipranavir (Aptivus) (J05AE09)
CL Item
Darunavir (TMC-114, Prezista) (J05AE10)
CL Item
NRTI unspecified (J05AF)
CL Item
Alovudine (J05AF-ALO)
CL Item
Amdoxovir (DADP) (J05AF-AMD)
CL Item
Fozivudine tidoxi (J05AF-FOZ)
CL Item
Lodenosine (trialdrug) (J05AF-LDN)
CL Item
Reverset (J05AF-RVT)
CL Item
Zidovudine (AZT, RETROVIR) (J05AF01)
CL Item
Didanosine (ddI) (VIDEX) (J05AF02)
CL Item
Zalcitabine (ddC) (HIVID) (J05AF03)
CL Item
Stavudine (d4T) (ZERIT) (J05AF04)
CL Item
Lamivudine (3TC, EPIVIR) (J05AF05)
CL Item
Abacavir (1592U89) (ZIAGEN) (J05AF06)
CL Item
Tenofovir (VIREAD) (J05AF07)
CL Item
Adefovir (PREVEON) (J05AF08)
CL Item
Emtricitabine (J05AF09)
CL Item
Entecavir (J05AF10)
CL Item
Telbivudine (J05AF11)
CL Item
NNRTI unspecified (J05AG)
CL Item
Etravirine (TMC 125) (J05AG04)
CL Item
Rilpivirine (TMC-278) (J05AG05)
CL Item
Capravirine (J05AG-CPV)
CL Item
DPC 083 (J05AG-DPC083)
CL Item
DPC 961 (J05AG-DPC961)
CL Item
Emivirine (MKC442) (J05AG-EMV)
CL Item
Loviride (J05AG-LOV)
CL Item
Nevirapine (VIRAMUN) (J05AG01)
CL Item
Delavirdine (U-90152) (RESCRIPTOR) (J05AG02)
CL Item
Efavirenz (DMP-266) (STOCRIN, SUSTIVA) (J05AG03)
CL Item
Combivir (Zidovudine/Lamivudine) (J05AR01)
CL Item
Kivexa (Lamivudine/Abacavir) (J05AR02)
CL Item
Truvada (Tenofovir/Emtricabine) (J05AR03)
CL Item
Trizivir (Zidovudine/Lamivudine/Abacavir) (J05AR04)
CL Item
Douvir-N (Zidovudine/Lamivudine/Nevirapine) (J05AR05)
CL Item
Atripla (Emtricitabine/Tenofovir/Efavirenz) (J05AR06)
CL Item
Triomune (Stavudine/Lamivudine/Nevirapine) (J05AR07)
CL Item
Eviplera/Complera (Emtricitabine/Tenofovir/Rilpivirine) (J05AR08)
CL Item
Stribild (Emtricitabine/Tenofovir/Elvitegravir/Cobicistat) (J05AR09)
CL Item
Kaletra/Aluvia (Lopinavir/Ritonavir) (J05AR10)
CL Item
Vicriviroc (Schering) (J05AX-VIC)
CL Item
Enfuvirtide (Fuzeon, T-20) (J05AX07)
CL Item
Raltegravir (Merck) (J05AX08)
CL Item
Maraviroc (Pfizer) (J05AX09)
CL Item
Elvitegravir (J05AX11)
CL Item
Dolutegravir (J05AX12)
CL Item
Hydroxyurea/Hydroxycarbamid (Litalir) (L01XX05)
CL Item
Cobicistat (V03AX03)
ART_SD
Item
Date of initiation of treatment
date
C1963724 (UMLS CUI [1,1])
C0808070 (UMLS CUI [1,2])
ART_ED
Item
Date of stopping treatment
date
C1963724 (UMLS CUI [1,1])
C0806020 (UMLS CUI [1,2])
Item
Reason for stopping treatment
integer
C2133636 (UMLS CUI [1,1])
C1963724 (UMLS CUI [1,2])
ART_RS
Code List
Reason for stopping treatment
CL Item
Treatment failure (i.e. virological, immunological, and/or clinical failure (1)
CL Item
Virological failure (1.1)
CL Item
Partial virological failure (1.2)
CL Item
Immunological failure - CD4 drop (1.3)
CL Item
Clinical progression (1.4)
CL Item
Abnormal fat redistribution (2)
CL Item
Concern of cardiovascular disease (3)
CL Item
Dyslipidaemia (3.1)
CL Item
Cardiovascular disease (3.2)
CL Item
Hypersensitivity reaction (4)
CL Item
Toxicity, predominantly from abdomen/G-I tract (5)
CL Item
Toxicity - GI tract (5.1)
CL Item
Toxicity - Liver (5.2)
CL Item
Toxicity - Pancreas (5.3)
CL Item
Toxicity, predominantly from nervous system (6)
CL Item
Toxicity - peripheral neuropathy (6.1)
CL Item
Toxicity - neuropsychiatric (6.2)
CL Item
Toxicity - headache (6.3)
CL Item
Toxicity, predominantly from kidneys (7)
CL Item
Toxicity, predominantly from endocrine system (8)
CL Item
Diabetes (8.1)
CL Item
Haematological toxicity (anemia etc.) (9)
CL Item
Hyperlactataemie/lactic acidosis (10)
CL Item
Death (88)
CL Item
Side effects - any of the above but unspecified (90)
CL Item
Comorbidity (90.1)
CL Item
Toxicity, not mentioned above (91)
CL Item
Toxicity, unspecified (91.1)
CL Item
Availability of more effective treatment (not specifically failure or side effect related) (92)
CL Item
Simplified treatment available (92.1)
CL Item
Treatment too complex (92.2)
CL Item
Drug interaction (92.3)
CL Item
Drug interaction - commencing TB/BCG treatment (92.31)
CL Item
Drug interaction - ended TB/BCG treatment (92.32)
CL Item
Change in eligibility criteria (e.g. child old enough for tablets; refrigerator no longer available) (92.33)
CL Item
Protocol change (92.4)
CL Item
Change in treatment not due to side-effects, failure, poor adherence or contra-indication (92.9)
CL Item
Structured Treatment Interruption (STI) (93)
CL Item
Structured Treatment Interruption (STI) - at high CD4 (93.1)
CL Item
Patient's wish/decision, not specified above (94)
CL Item
Non-compliance (94.1)
CL Item
Defaulter (94.2)
CL Item
Physician's decision, not specified above (95)
CL Item
Pregnancy (96)
CL Item
Pregnancy intended (96.1)
CL Item
Pregnancy ended (96.2)
CL Item
Study treatment (97)
CL Item
Study treatment commenced (97.1)
CL Item
Study treatment completed (97.2)
CL Item
Drug not available (97.6)
CL Item
Other causes, not specified above (98)
CL Item
Unknown (99)
ART_DO
Item
Dosage (mg or mL) per intake unless ART_FR=-1
float
C3174092 (UMLS CUI [1,1])
C1963724 (UMLS CUI [1,2])
ART_FR
Item
Frequency
integer
C3476109 (UMLS CUI [1,1])
C1963724 (UMLS CUI [1,2])
ART_ST
Item
Start hour and minute of the day
time
C1963724 (UMLS CUI [1,1])
C1301880 (UMLS CUI [1,2])
ART_ET
Item
Stop hour and minute of the day
time
C1963724 (UMLS CUI [1,1])
C1522314 (UMLS CUI [1,2])
Back to the top of the page